DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia

Recruiting

Conditions: Unresectable /Inoperable Locally Advanced (Stage II-III) NSCLC and Locally Advanced LS-SCLC (Stage I-III)

First Posted Date: 2023-06-02

Last Posted Date: 2025-05-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 2000

Registration Number: NCT05887011

Locations: 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 3

Active, not recruiting

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2023-06-01

Last Posted Date: 2025-05-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 111

Registration Number: NCT05883644

Locations: 🇻🇳
Research Site, Hanoi, Vietnam

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Phase 1

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Colorectal Carcinoma
Breast Cancer
Pancreatic Adenocarcinoma
Other Solid Tumors
Non-small Cell Lung Cancer
Ovarian Cancer

Interventions: Biological: Autologous, engineered T Cells targeting TP53 R175H

First Posted Date: 2023-05-26

Last Posted Date: 2025-05-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 162

Registration Number: NCT05877599

Locations: 🇺🇸
Research Site, Round Rock, Texas, United States

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

Phase 1

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: AZD3152
Other: Placebo

First Posted Date: 2023-05-24

Last Posted Date: 2024-06-12

Lead Sponsor: AstraZeneca

Target Recruit Count: 98

Registration Number: NCT05872958

Locations: 🇺🇸
Research Site, Orlando, Florida, United States

To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients

Completed

Conditions: Chronic Kidney Disease

First Posted Date: 2023-05-19

Last Posted Date: 2025-03-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 1426

Registration Number: NCT05866276

Locations: 🇮🇩
Research Site, Surabaya, Indonesia
🇮🇩
Perisai Husada, Bandung, Jawa Barat, Indonesia
🇻🇳
Nguyen Tri Phuong Hospital, Ho Chi Minh City, Vietnam

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Phase 1

Terminated

Conditions: Steatohepatitis

Interventions: Drug: AZD7503

First Posted Date: 2023-05-18

Last Posted Date: 2024-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 40

Registration Number: NCT05864391

Locations: 🇵🇷
Research Site, San Juan, Puerto Rico

Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)

Active, not recruiting

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: BGF (budesonide/glycopyrrolate/formoterol fumarate)

First Posted Date: 2023-05-17

Last Posted Date: 2025-03-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 250

Registration Number: NCT05862545

Locations: 🇮🇹
Research Site, Verona, Italy

Study to Assess Bronchospasm Potentially Induced by HFO vs HFA MDI in Participants With Well/Partially Controlled Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: HFA MDI
Drug: HFO MDI

First Posted Date: 2023-05-09

Last Posted Date: 2023-09-28

Lead Sponsor: AstraZeneca

Target Recruit Count: 52

Registration Number: NCT05850494

Locations: 🇺🇸
Research Site, El Paso, Texas, United States

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Relapsed/ Refractory Multiple Myeloma

Interventions: Biological: GC012F (AZD0120)

First Posted Date: 2023-05-09

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 80

Registration Number: NCT05850234

Locations: 🇺🇸
Research Site, Milwaukee, Wisconsin, United States

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Phase 1

Completed

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: AZD9550
Drug: Placebo

First Posted Date: 2023-05-08

Last Posted Date: 2023-12-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT05848440

Locations: 🇬🇧
Research Site, Harrow, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy